Date：December 12,2025
Agenda：
14:00-14:03 Introduction of participants, speakers and schedule
14:03-14:10 Welcome Remarks
14:10-14:30 Value Proposition for Vaccine Development
14:30-14:50 Target Product Profile
14:50-15:10 Integrated Product Development Plan
15:10-15:20 Q&A
15:20-15:30 Closing Remarks
Speakers introduction:
Ms. Yuan Yuan
Yuan Yuan, Secretary-General of CPIVC, has been working at PATH since January 2007, serving as Project Assistant, Project Administrator, Project Manager and Alliance Manager. She is currently the Country Representative in China, responsible for PATH's commercial and business development in China. During the 18 years of working in the vaccine field, she participated in WHO precertification of JE vaccine, rotavirus vaccine development, pneumonia conjugate vaccine development and training, OPV overseas clinical practice, Sabin IPV D antigen international standard development, HPV vaccine precertification and other projects. Familiar with vaccine life cycle production, quality, clinical, drug administration, pharmacovigilance, biosafety and other aspects. Prior to joining PATH, she was a project manager at Integrity Metals in Singapore and worked in Indonesia.
Ms. Feng Dongyang
Ms. Feng Dongyang has been with Program for Appropriate Technology in Health (PATH) since March 2022. Currently serving as a Project Manager, she provides technical and project management support for PATH’s vaccine-related initiatives in China. With 13 years of professional experience in the vaccine sector, she possesses comprehensive expertise across the full vaccine life cycle, covering manufacturing, quality assurance, and regulatory affairs. Prior to joining PATH, she worked as a Prequalification and Regulatory Supervisor in the quality assurance department at Wuhan Institute of Biological Products Co., Ltd.
Ms. Han Qing
Ms. Han Qing is currently a Project Manager at the Center for Vaccine Innovation and Access, PATH. Since joining PATH in 2019, she has dedicated her expertise entirely to the vaccine sector, leveraging professional project management practices to advance vaccine development and expand equitable supply in China and other low- and middle-income countries (LMICs).With an in-depth command of the full vaccine life cycle, Ms. Han has amassed extensive project management experience across the entire value chain--encompassing R&D, clinical trials, manufacturing scale-up, and post-marketing surveillance. Her portfolio features a series of high-impact initiatives pivotal to global public health, including the WHO prequalification of HPV vaccines, overseas clinical trials of yellow fever vaccines, upgrading and qualification of rotavirus vaccine production facilities, research on COVID-19 monoclonal antibodies, capacity-building programs for vaccine development and global access, and post-marketing pharmacovigilance of vaccines.
Original links: https://mp.weixin.qq.com/s/FX9f3o_lNI9Sg1PMSZ2YPA
京公网安备 11010802041931号 © 2024 cpivc.com